Cardinal Health INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Cardinal Health reported an 11% increase in revenue for the third quarter of fiscal year 2026, driven by strong performance in its Pharmaceutical and Specialty Solutions segment.
NYSE
Cardinal Health announced robust financial results for Q2 fiscal year 2026, with significant revenue and earnings growth fueled by strategic acquisitions and strong performance across its segments.
NYSE
Cardinal Health reports a robust start to fiscal year 2026 with significant revenue and operating earnings growth, driven by strategic acquisitions and strong pharmaceutical sales.
NYSE
10-Q: Cardinal Health Reports Q3 Fiscal 2025 Results: Earnings Surge Driven by Pharma Segment Growth
Cardinal Health's Q3 Fiscal 2025 shows a significant increase in GAAP and non-GAAP operating earnings, driven by pharmaceutical segment growth and strategic acquisitions.
NYSE
10-Q: Cardinal Health Reports Mixed Q2 Results Amidst Strategic Acquisitions and Contract Expirations
Cardinal Health's second quarter fiscal 2025 results show a revenue decrease due to contract expirations, offset by growth in other areas and strategic acquisitions.
NYSE
Cardinal Health's first quarter fiscal 2025 results show a revenue decrease of 4% due to the expiration of a major contract, though non-GAAP operating earnings increased by 12%.
NYSE
Cardinal Health's Q3 fiscal 2024 results show a 9% revenue increase, driven by pharmaceutical sales, while also navigating significant strategic changes including a new segment structure and the non-renewal of a major contract.
NYSE
Cardinal Health's second quarter fiscal year 2024 shows a 12% revenue increase, driven by pharmaceutical sales, alongside a strategic realignment of its reporting segments.